Rethinking Diabetes Treatment: The Shift Toward Remission
The approach to managing diabetes mellitus is undergoing a fundamental transformation. Rather than solely focusing on blood sugar control, emphasis is shifting towards achieving remission, early detection, and innovative medications. Recent research presents promising developments in this field.
Remission Without Medication: 18% Achieve Success
A dietary change holds the potential to reverse Type 2 diabetes. Researchers from Australia’s La Trobe University revealed significant findings in July 2026: 18% of participants achieved remission without medication, merely through reduced carbohydrate intake. Remission is defined as maintaining blood sugar levels below the diagnostic threshold for at least three months. Notably, 78% of participants improved their health markers overall.
Long-term data substantiates these trends. The DiRECT study demonstrated a remission rate of 46% after one year, tapering to around 25% after five years. A Norwegian study conducted in May 2026 examined various dietary methods: rapid weight loss through a strict 1,000-calorie-per-day diet showed a 14.4% reduction in weight after one year, while a moderate diet achieved a loss of 10.5% without significant yo-yo effects.
Technology: Continuous Glucose Monitoring in Primary Care
Modern technology is increasingly becoming integral to widespread healthcare. A U.S. study conducted between August 2022 and August 2025 confirmed the benefits of Continuous Glucose Monitoring (CGM) systems in general practice. Among more than 8,500 participants, the prescription of such systems resulted in clinically relevant reductions in HbA1c levels and decreased hospitalization rates.
Interestingly, only three minutes of daily effort can help Type 2 diabetes patients lower their blood sugar naturally. A free guidebook outlines seven simple exercises with immediate effects, requiring no gym membership. 7 Simple 3-Minute Exercises with Immediate Effects
Meanwhile, early detection of Type 1 diabetes in children is gaining attention. The Fr1da study in Bavaria, published in July 2026 in JAMA, highlights the feasibility of extensive screenings. Since February 2015, over 220,000 children have been tested for island autoantibodies, identifying 0.3% at an early stage. The progression to clinical Type 1 diabetes occurred in 36.2% within five years.
New Medications: Semaglutide Tablet Launches in September
The introduction of a Semaglutide tablet in Germany is set for September 2026, following EU approval. The OASIS-4 study indicated an average weight loss of 16.6% with proper usage. However, experts caution that this medication may lead to a rebound effect upon discontinuation. Additionally, a July 2026 investigation in the BMJ revealed a 37% increased risk of hair loss associated with GLP-1 receptor agonists, though the absolute risk remains low.
A plant-based compound, Totum·63, also shows potential. The REVERSE-IT study, involving 636 participants and published in July 2026 in Nature Communications, demonstrated a significant decrease in fasting blood sugar among individuals with prediabetes or early Type 2 diabetes.
Since January 2026, Teplizumab has been approved in Germany for Type 1 diabetes. Clinical trials such as BARICADE DELAY and ?ETA PRESERVE are currently investigating additional applications of immunotherapy across different age groups and stages of the disease.
Sugar Tax and Systemic Debates: Addressing Structural Issues
Alongside medical advancements, structural questions are shaping the discussion. An expert commission addressed the potential introduction of a sugar tax on soft drinks in summer 2026 as a means to stabilize the statutory health insurance system. Model calculations from 2023 suggest that significant sugar reduction could prevent up to 250,000 cases of Type 2 diabetes.
The German Diabetes Society (DDG) raised concerns in early July 2026 about the adverse effects of the GKV contribution rate stabilization law. They fear it could jeopardize quality care in certified diabetes centers. Moreover, a roadmap led by the Luxembourg Institute of Health (LIH) aims for a human-AI symbiosis by 2050 to enhance the quality of life for affected individuals, noting that around a quarter of diabetics currently suffer from emotional exhaustion.
